238 related articles for article (PubMed ID: 22247228)
21. Paraoxonase-1 (PON1) activity as a risk factor for atherosclerosis in chronic renal failure patients.
Saeed SA; Elsharkawy M; Elsaeed K; Fooda O
Hemodial Int; 2008 Oct; 12(4):471-9. PubMed ID: 19090870
[TBL] [Abstract][Full Text] [Related]
22. Paraoxonase-1 concentrations in end-stage renal disease patients increase after hemodialysis: correlation with low molecular AGE adduct clearance.
Gugliucci A; Mehlhaff K; Kinugasa E; Ogata H; Hermo R; Schulze J; Kimura S
Clin Chim Acta; 2007 Feb; 377(1-2):213-20. PubMed ID: 17118352
[TBL] [Abstract][Full Text] [Related]
23. Effect of non-genetic factors on paraoxonase 1 activity in patients undergoing hemodialysis.
Rajković MG; Rumora L; Juretić D; Grubisić TZ; Flegar-Mestrić Z; Vrkić N; Sinjeri Z; Barisić K
Clin Biochem; 2010 Dec; 43(18):1375-80. PubMed ID: 20807524
[TBL] [Abstract][Full Text] [Related]
24. Human paraoxonase-1 activity in childhood obesity and its relation to leptin and adiponectin levels.
Koncsos P; Seres I; Harangi M; Illyés I; Józsa L; Gönczi F; Bajnok L; Paragh G
Pediatr Res; 2010 Mar; 67(3):309-13. PubMed ID: 19915520
[TBL] [Abstract][Full Text] [Related]
25. Active visfatin is elevated in serum of maintenance haemodialysis patients and correlates inversely with circulating HDL cholesterol.
Nüsken KD; Petrasch M; Rauh M; Stöhr W; Nüsken E; Schneider H; Dötsch J
Nephrol Dial Transplant; 2009 Sep; 24(9):2832-8. PubMed ID: 19389865
[TBL] [Abstract][Full Text] [Related]
26. Serum paraoxonase phenotype distribution in exudative age-related macular degeneration and its relationship to homocysteine and oxidized low-density lipoprotein.
Javadzadeh A; Ghorbanihaghjo A; Bahreini E; Rashtchizadeh N; Argani H; Alizadeh S
Retina; 2012 Apr; 32(4):658-66. PubMed ID: 22030834
[TBL] [Abstract][Full Text] [Related]
27. Cardiovascular risk factors in hemodialysis and peritoneal dialysis patients.
Helal I; Smaoui W; Hamida FB; Ouniss M; Aderrahim E; Hedri H; Elyounsi F; Maiz HB; Abdallah TB; Kheder A
Saudi J Kidney Dis Transpl; 2010 Jan; 21(1):59-62. PubMed ID: 20061694
[TBL] [Abstract][Full Text] [Related]
28. Paraoxonase 1 activities and genetic variation in childhood obesity.
Rupérez AI; López-Guarnido O; Gil F; Olza J; Gil-Campos M; Leis R; Tojo R; Cañete R; Gil A; Aguilera CM
Br J Nutr; 2013 Nov; 110(9):1639-47. PubMed ID: 23789921
[TBL] [Abstract][Full Text] [Related]
29. Effects of calcineurin inhibitors on paraoxonase and arylesterase activity after a kidney transplant.
Kahvecioglu S; Ersoy A; Gullulu M; Dirican M
Exp Clin Transplant; 2014 Aug; 12(4):334-42. PubMed ID: 24447269
[TBL] [Abstract][Full Text] [Related]
30. Inverse correlation of serum paraoxonase and homocysteine thiolactonase activities and antioxidant capacity of high-density lipoprotein with the severity of cardiovascular disease in persons with type 2 diabetes mellitus.
Lakshman MR; Gottipati CS; Narasimhan SJ; Munoz J; Marmillot P; Nylen ES
Metabolism; 2006 Sep; 55(9):1201-6. PubMed ID: 16919539
[TBL] [Abstract][Full Text] [Related]
31. Paraoxonase 1 activity as a predictor of cardiovascular disease in type 2 diabetes.
Poh R; Muniandy S
Southeast Asian J Trop Med Public Health; 2010 Sep; 41(5):1231-46. PubMed ID: 21073045
[TBL] [Abstract][Full Text] [Related]
32. Polymorphisms of pon1 and pon2 genes in hemodialyzed patients.
Rajković MG; Barišić K; Juretić D; Grubišić TŽ; Flegar-Meštrić Z; Rumora L
Clin Biochem; 2011 Aug; 44(12):964-8. PubMed ID: 21620813
[TBL] [Abstract][Full Text] [Related]
33. Activation of paraoxonase 1 after hemodialysis is associated with HDL remodeling and its increase in the HDL2 fraction and VLDL.
Gugliucci A; Kinugasa E; Ogata H; Caccavello R; Kimura S
Clin Chim Acta; 2014 Mar; 430():9-14. PubMed ID: 24384301
[TBL] [Abstract][Full Text] [Related]
34. Paraoxonase activity in healthy, diabetic, and hemodialysis patients.
Gbandjaba NY; Ghalim N; Hassar M; Berrougui H; Labrazi H; Taki H; Saile R; Khalil A
Clin Biochem; 2012 Apr; 45(6):470-4. PubMed ID: 22285382
[TBL] [Abstract][Full Text] [Related]
35. Osteoprotegerin as a predictor of renal and cardiovascular outcomes in renal transplant recipients: follow-up data from the ALERT study.
Svensson M; Dahle DO; Mjøen G; Weihrauch G; Scharnagl H; Dobnig H; März W; Jardine A; Fellström B; Holdaas H
Nephrol Dial Transplant; 2012 Jun; 27(6):2571-5. PubMed ID: 22172725
[TBL] [Abstract][Full Text] [Related]
36. Longitudinal changes in PON1 activities, PON1 phenotype distribution and oxidative status throughout normal pregnancy.
Stefanović A; Ardalic D; Kotur-Stevuljević J; Vujović A; Spasic S; Spasojević-Kalimanovska V; Jelic-Ivanovic Z; Mandic-Markovic V; Mikovic Z; Cerovic N
Reprod Toxicol; 2012 Jan; 33(1):20-6. PubMed ID: 22074696
[TBL] [Abstract][Full Text] [Related]
37. Investigation of the relationship between atherosclerosis and paraoxonase or homocysteine thiolactonase activity in patients with type 2 diabetes mellitus using a commercially available assay.
Kosaka T; Yamaguchi M; Motomura T; Mizuno K
Clin Chim Acta; 2005 Sep; 359(1-2):156-62. PubMed ID: 15927175
[TBL] [Abstract][Full Text] [Related]
38. Increased oxidized-LDL levels and arylesterase activity/HDL ratio in ESRD patients treated with hemodialysis.
Mahrooz A; Zargari M; Sedighi O; Shaygani H; Gohari G
Clin Invest Med; 2012 Jun; 35(3):E144-51. PubMed ID: 22673317
[TBL] [Abstract][Full Text] [Related]
39. Associations of adiponectin with paraoxonase 1 and sE-selectin in hemodialyzed patients.
Peti A; Csiky B; Guth E; Kenyeres P; Varga Z; Seres I; Jeney Z; Juhasz M; Mezosi E; Paragh G; Kovacs GL; Bajnok L
Kidney Blood Press Res; 2009; 32(5):360-5. PubMed ID: 19887823
[TBL] [Abstract][Full Text] [Related]
40. Activity of paraoxonase 1 (PON1) on HDL
Miljkovic M; Stefanovic A; Vekic J; Zeljkovic A; Gojkovic T; Simic-Ogrizovic S; Bogavac-Stanojevic N; Cerne D; Ilic J; Stefanovic I; Jelic-Ivanovic Z; Spasojevic-Kalimanovska V; Kotur-Stevuljevic J
Clin Biochem; 2018 Sep; 60():52-58. PubMed ID: 30130521
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
